TY - JOUR
T1 - Clinical Characteristics and Treatment Patterns of Children and Adults With IgA Nephropathy or IgA Vasculitis
T2 - Findings From the CureGN Study
AU - CureGN Consortium
AU - Selewski, David T.
AU - Ambruzs, Josephine M.
AU - Appel, Gerald B.
AU - Bomback, Andrew S.
AU - Matar, Raed Bou
AU - Cai, Yi
AU - Cattran, Daniel C.
AU - Chishti, Aftab S.
AU - D'Agati, Vivette D.
AU - D'Alessandri-Silva, Cynthia J.
AU - Gbadegesin, Rasheed A.
AU - Hogan, Jonathan J.
AU - Iragorri, Sandra
AU - Jennette, J. Charles
AU - Julian, Bruce A.
AU - Khalid, Myda
AU - Lafayette, Richard A.
AU - Liapis, Helen
AU - Lugani, Francesca
AU - Mansfield, Sarah A.
AU - Mason, Sherene
AU - Nachman, Patrick H.
AU - Nast, Cynthia C.
AU - Nester, Carla M.
AU - Noone, Damien G.
AU - Novak, Jan
AU - O'Shaughnessy, Michelle M.
AU - Reich, Heather N.
AU - Rheault, Michelle N.
AU - Rizk, Dana V.
AU - Saha, Manish K.
AU - Sanghani, Neil S.
AU - Sperati, C. John
AU - Sreedharan, Rajasree
AU - Srivastava, Tarak
AU - Swiatecka-Urban, Agnieszka
AU - Twombley, Katherine
AU - Vasylyeva, Tetyana L.
AU - Weaver, Donald J.
AU - Yin, Hong
AU - Zee, Jarcy
AU - Falk, Ronald J.
AU - Gharavi, Ali G.
AU - Gillespie, Brenda W.
AU - Gipson, Debbie S.
AU - Greenbaum, Larry A.
AU - Holzman, Lawrence B.
AU - Kretzler, Matthias
AU - Robinson, Bruce M.
AU - Smoyer, William E.
AU - Flessner, Michael
AU - Guay-Woodford, Lisa M.
AU - Kiryluk, Krzysztof
AU - Ahn, Wooin
AU - Avasare, Rupali S.
AU - Babayev, Revekka
AU - Batal, Ibrahim
AU - Brown, Eric
AU - Campenot, Eric S.
AU - Canetta, Pietro
AU - Chan, Brenda
AU - Fernandez, Hilda
AU - Foroncewicz, Bartosz
AU - Ghiggeri, Gian Marco
AU - Hines, William H.
AU - Jain, Namrata G.
AU - Lin, Fangming
AU - Marasa, Maddalena
AU - Markowitz, Glen
AU - Mohan, Sumit
AU - Mucha, Krzysztof
AU - Nickolas, Thomas L.
AU - Radhakrishnan, Jai
AU - Rao, Maya K.
AU - Regunathan-Shenk, Renu
AU - Sanna-Cherchi, Simone
AU - Santoriello, Dominick
AU - Stokes, Michael B.
AU - Yu, Natalie
AU - Valeri, Anthony M.
AU - Zviti, Ronald
AU - Al-Uzri, Amira
AU - Ashoor, Isa
AU - Aviles, Diego
AU - Baracco, Rossana
AU - Barcia, John
AU - Bartosh, Sharon
AU - Belsha, Craig
AU - Braun, Michael C.
AU - Claes, Donna
AU - Cramer, Carl
AU - Davis, Keefe
AU - Erkan, Elif
AU - Feig, Daniel
AU - Freundlich, Michael
AU - Hanna, Melisha
AU - Hidalgo, Guillermo
AU - Jain, Amrish
AU - Kallash, Mahmoud
AU - Lane, Jerome C.
N1 - Publisher Copyright:
© 2018 International Society of Nephrology
PY - 2018/11/1
Y1 - 2018/11/1
N2 - Introduction: The Cure Glomerulonephropathy Network (CureGN) is a 66-center longitudinal observational study of patients with biopsy-confirmed minimal change disease, focal segmental glomerulosclerosis, membranous nephropathy, or IgA nephropathy (IgAN), including IgA vasculitis (IgAV). This study describes the clinical characteristics and treatment patterns in the IgA cohort, including comparisons between IgAN versus IgAV and adult versus pediatric patients. Methods: Patients with a diagnostic kidney biopsy within 5 years of screening were eligible to join CureGN. This is a descriptive analysis of clinical and treatment data collected at the time of enrollment. Results: A total of 667 patients (506 IgAN, 161 IgAV) constitute the IgAN/IgAV cohort (382 adults, 285 children). At biopsy, those with IgAV were younger (13.0 years vs. 29.6 years, P < 0.001), more frequently white (89.7% vs. 78.9%, P = 0.003), had a higher estimated glomerular filtration rate (103.5 vs. 70.6 ml/min per 1.73 m2, P < 0.001), and lower serum albumin (3.4 vs. 3.8 g/dl, P < 0.001) than those with IgAN. Adult and pediatric individuals with IgAV were more likely than those with IgAN to have been treated with immunosuppressive therapy at or prior to enrollment (79.5% vs. 54.0%, P < 0.001). Conclusion: This report highlights clinical differences between IgAV and IgAN and between children and adults with these diagnoses. We identified differences in treatment with immunosuppressive therapies by disease type. This description of baseline characteristics will serve as a foundation for future CureGN studies.
AB - Introduction: The Cure Glomerulonephropathy Network (CureGN) is a 66-center longitudinal observational study of patients with biopsy-confirmed minimal change disease, focal segmental glomerulosclerosis, membranous nephropathy, or IgA nephropathy (IgAN), including IgA vasculitis (IgAV). This study describes the clinical characteristics and treatment patterns in the IgA cohort, including comparisons between IgAN versus IgAV and adult versus pediatric patients. Methods: Patients with a diagnostic kidney biopsy within 5 years of screening were eligible to join CureGN. This is a descriptive analysis of clinical and treatment data collected at the time of enrollment. Results: A total of 667 patients (506 IgAN, 161 IgAV) constitute the IgAN/IgAV cohort (382 adults, 285 children). At biopsy, those with IgAV were younger (13.0 years vs. 29.6 years, P < 0.001), more frequently white (89.7% vs. 78.9%, P = 0.003), had a higher estimated glomerular filtration rate (103.5 vs. 70.6 ml/min per 1.73 m2, P < 0.001), and lower serum albumin (3.4 vs. 3.8 g/dl, P < 0.001) than those with IgAN. Adult and pediatric individuals with IgAV were more likely than those with IgAN to have been treated with immunosuppressive therapy at or prior to enrollment (79.5% vs. 54.0%, P < 0.001). Conclusion: This report highlights clinical differences between IgAV and IgAN and between children and adults with these diagnoses. We identified differences in treatment with immunosuppressive therapies by disease type. This description of baseline characteristics will serve as a foundation for future CureGN studies.
KW - glomerulonephritis
KW - Henoch-Schönlein purpura (HSP)
KW - IgA nephropathy (IgAN)
KW - IgA vasculitis (IgAV)
UR - https://www.scopus.com/pages/publications/85055727446
U2 - 10.1016/j.ekir.2018.07.021
DO - 10.1016/j.ekir.2018.07.021
M3 - Article
AN - SCOPUS:85055727446
SN - 2468-0249
VL - 3
SP - 1373
EP - 1384
JO - Kidney International Reports
JF - Kidney International Reports
IS - 6
ER -